Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988

Cocrystal Pharma, Inc.

FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.
CDI-988 is first oral antiviral candidate for both treatment and prophylaxis of norovirus infection.
Phase 1b double-blind challenge study (NCT07198139) ongoing at Emory University in up to 40 adults.
Norovirus causes ~685M global infections/year with ~$60B worldwide economic impact.
Fast Track enables rolling NDA review and potential Priority Review; no financial terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.